Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ongoing negotiations with the U.S. administration over potential pharmaceuticals tariffs.
Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG
Get this delivered to your inbox, and more info about our products and services.
Novartis comprerà Avidity Biosciences per 12 miliardi di dollari
Novartis to buy Avidity Biosciences for $12bn
Novartis kauft Avidity für zwölf Milliarden Dollar
Novartis compra Avidity Biosciences per 12 miliardi di dollari
Novartis compra Avidity Biosciences per 12 miliardi di dollari - Notizie - Ansa.it
Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
Novartis CEO Vas Narasimhan told CNBC in Davos that he believes the Swiss drugmaker is protected from any additional U.S. tariffs…
Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences…
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.
